Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + SC-EPOCH-R for newly diagnosed HIV-related diffuse large B-cell lymphoma
ChiCTR2300069941Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL) and human immunodeficiency virus infection (HIV), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Complete response rate. Started Feb 2023; status: recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2300069941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069941.